EPISODE · Apr 6, 2026 · 15 MIN
Neurocrine Acquires Soleno for $2.9 Billion to Boost Rare Obesity Disorder Portfolio
from AI Daily Pulse · host Healthcare Daily Pulse
Intelligence Brief:Neurocrine Acquires Soleno for $2.9 Billion to Boost Rare Obesity Disorder PortfolioGilead Acquires Ouro Medicines for $2.2 BillionExpanding Autoimmune PipelineCMS Finalizes Extensive Policy Changes for Medicare Advantage and Part D in 2027Hologic CEO Stephen MacMillan Retires Amid Blackstone and TPG Buyout ClosureHeidi Partners with R1 to Integrate AI-Powered Documentation with Revenue Cycle Management## Healthcare Daily Pulse: Rapid-Fire Q3 Market Shifts **Hosts:** * **Alex:** Skeptical Financial Analyst (Payor expert). Technical, critical, implementation-focused. * **Sam:** Optimistic Market Visionary (ROI/Competitive Strategy expert). Pragmatic but forward-looking. --- **(0:00 - 0:45) INTRO** **Alex:** Welcome back to Healthcare Daily Pulse, your rapid-fire dive into the financial and operational seismic shifts shaking the healthcare landscape. I'm Alex, dissecting the P&L impacts ...
Embed this episode
NOW PLAYING
Neurocrine Acquires Soleno for $2.9 Billion to Boost Rare Obesity Disorder Portfolio
No transcript for this episode yet
Similar Episodes
No similar episodes found.